Answers are grounded in this paper and cite their sources.
Experimental study reveals that central melanocortin pathway activation mediates fenfluramine-induced appetite suppression in rodents, highlighting a selective target for obesity treatments.
D-fenfluramine (d-FEN) was once widely prescribed and was among the most effective weight loss drugs, but was withdrawn from clinical use because of reports of cardiac complications in a subset of patients. Discerning the neurobiology underlying the anorexic action of d-FEN may facilitate the development of new drugs to prevent and treat obesity. Through a combination of functional neuroanatomy, feeding, and electrophysiology studies in rodents, we show that d-FEN-induced anorexia requires activation of central nervous system melanocortin pathways. These results provide a mechanistic explanation of d-FEN's anorexic actions and indicate that drugs targeting these downstream melanocortin pathways may prove to be effective and more selective anti-obesity treatments.
No takes yet. Share an insight, caveat, or question.
Heisler et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: